1. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry. 2003;64 Suppl 16:24–33.
2. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209–22.
3. Johnson DAW, Pasterski JM, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983;67:339–52.
4. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst. 1976;37:494–500.
5. Hogarty GE, Schooler NR, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of two year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36:1283–94.